Cite
MLA Citation
G. Garcia-Manero et al.. “112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS).” Leukemia research, vol. 39, n.d., pp. S57–S58. http://access.bl.uk/ark:/81055/vdc_100059908853.0x000001